AU2011305568B2 - Imidazotriazinone compounds - Google Patents

Imidazotriazinone compounds Download PDF

Info

Publication number
AU2011305568B2
AU2011305568B2 AU2011305568A AU2011305568A AU2011305568B2 AU 2011305568 B2 AU2011305568 B2 AU 2011305568B2 AU 2011305568 A AU2011305568 A AU 2011305568A AU 2011305568 A AU2011305568 A AU 2011305568A AU 2011305568 B2 AU2011305568 B2 AU 2011305568B2
Authority
AU
Australia
Prior art keywords
alkyl
imidazo
trans
triazin
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011305568A
Other languages
English (en)
Other versions
AU2011305568A1 (en
Inventor
Andrew Mcriner
Amy Ripka
Gideon Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Publication of AU2011305568A1 publication Critical patent/AU2011305568A1/en
Assigned to FORUM PHARMACEUTICALS INC. reassignment FORUM PHARMACEUTICALS INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: ENVIVO PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2011305568B2 publication Critical patent/AU2011305568B2/en
Priority to AU2016200970A priority Critical patent/AU2016200970A1/en
Assigned to IRONWOOD PHARMACEUTICALS, INC. reassignment IRONWOOD PHARMACEUTICALS, INC. Request for Assignment Assignors: FORUM PHARMACEUTICALS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2011305568A 2010-09-20 2011-09-20 Imidazotriazinone compounds Ceased AU2011305568B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016200970A AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38469410P 2010-09-20 2010-09-20
US61/384,694 2010-09-20
PCT/US2011/052399 WO2012040230A1 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200970A Division AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Publications (2)

Publication Number Publication Date
AU2011305568A1 AU2011305568A1 (en) 2013-04-04
AU2011305568B2 true AU2011305568B2 (en) 2015-12-10

Family

ID=44720178

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011305568A Ceased AU2011305568B2 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds
AU2016200970A Abandoned AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016200970A Abandoned AU2016200970A1 (en) 2010-09-20 2016-02-16 Imidazotriazinone compounds

Country Status (16)

Country Link
US (3) US20120157458A1 (enExample)
EP (2) EP3181566A1 (enExample)
JP (2) JP5855109B2 (enExample)
CN (1) CN103313988B (enExample)
AR (1) AR083058A1 (enExample)
AU (2) AU2011305568B2 (enExample)
BR (1) BR112013008140A8 (enExample)
CA (1) CA2811714C (enExample)
DK (1) DK2619208T3 (enExample)
ES (1) ES2610360T3 (enExample)
MX (1) MX2013003093A (enExample)
PL (1) PL2619208T3 (enExample)
RU (1) RU2603140C2 (enExample)
TW (1) TWI541244B (enExample)
UY (1) UY33616A (enExample)
WO (1) WO2012040230A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2619208T3 (pl) * 2010-09-20 2017-03-31 Ironwood Pharmaceuticals, Inc. Związki imidazotriazynonu
HK1211023A1 (zh) * 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
EP3178820B1 (en) 2012-01-26 2017-12-20 H. Lundbeck A/S Pde9- inhibitors with imidazo triazinone backbone
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
WO2016147659A1 (en) * 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) * 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
TN2018000383A1 (en) 2016-07-06 2020-06-15 H Lundbeck As Pde9 inhibitors for treatment of peripheral diseases.
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
JP2019536762A (ja) 2016-10-28 2019-12-19 ハー・ルンドベック・アクチエゼルスカベット 精神疾患及び／又は認知障害の治療のためのイミダゾピラジノンを含む併用療法
KR20190077349A (ko) 2016-10-28 2019-07-03 하. 룬드벡 아크티에셀스카브 이미다조피라지논의 투여를 포함하는 병용 치료
CN115746003B (zh) * 2017-05-26 2024-08-09 卡都瑞恩医药公司 制备和使用pde9抑制剂的方法
ES2975792T3 (es) 2018-05-25 2024-07-15 Cardurion Pharmaceuticals Inc Monohidrato y formas cristalinas de 6-[(3s,4s)-4-metil-1- (pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7H-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
WO2020102374A1 (en) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Targeting of makap-pde4d3 complexes in neurodegenerative disease
KR102712818B1 (ko) * 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN114929231B (zh) * 2019-10-21 2024-11-29 爱思开生物制药株式会社 咪唑并嘧啶或咪唑并三嗪化合物用于预防、减轻或治疗发育性残疾的用途
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
CA2465632A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20060264624A1 (en) 2005-05-20 2006-11-23 Alexander Heim-Riether Methods for synthesizing imidazotriazinones
JP2008543968A (ja) 2005-06-28 2008-12-04 オーキッド リサーチ ラボラトリーズ リミテッド 新規なピラゾロピリミジノン誘導体
HRP20120105T1 (hr) * 2007-05-11 2012-02-29 Pfizer Inc. Aminoheterociklički spojevi
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
PL2619208T3 (pl) 2010-09-20 2017-03-31 Ironwood Pharmaceuticals, Inc. Związki imidazotriazynonu
EP3178820B1 (en) 2012-01-26 2017-12-20 H. Lundbeck A/S Pde9- inhibitors with imidazo triazinone backbone
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds

Also Published As

Publication number Publication date
WO2012040230A1 (en) 2012-03-29
RU2013118362A (ru) 2014-10-27
BR112013008140A2 (pt) 2017-12-05
PL2619208T3 (pl) 2017-03-31
TW201217381A (en) 2012-05-01
EP3181566A1 (en) 2017-06-21
US20170152265A1 (en) 2017-06-01
HK1187908A1 (en) 2014-04-17
JP5855109B2 (ja) 2016-02-09
RU2603140C2 (ru) 2016-11-20
BR112013008140A8 (pt) 2018-04-03
AR083058A1 (es) 2013-01-30
EP2619208A1 (en) 2013-07-31
CA2811714C (en) 2017-11-21
AU2011305568A1 (en) 2013-04-04
CN103313988A (zh) 2013-09-18
US20140330014A1 (en) 2014-11-06
CA2811714A1 (en) 2012-03-29
JP2016104747A (ja) 2016-06-09
US20120157458A1 (en) 2012-06-21
CN103313988B (zh) 2016-06-08
JP2013540755A (ja) 2013-11-07
MX2013003093A (es) 2013-10-28
DK2619208T3 (en) 2017-01-30
ES2610360T3 (es) 2017-04-27
AU2016200970A1 (en) 2016-03-03
TWI541244B (zh) 2016-07-11
US9540380B2 (en) 2017-01-10
UY33616A (es) 2012-04-30
EP2619208B1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
AU2011305568B2 (en) Imidazotriazinone compounds
US9969742B2 (en) Imidazotriazinone compounds
AU2013213603B2 (en) PDE9 inhibitors with imidazo triazinone backbone
US20230167118A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
US20150065465A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP3681885B1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
CN116209446B (zh) 作为毒蕈碱性乙酰胆碱受体m4的正向别构调节剂的7-(哌啶-1-基)-4h-嘧啶并[1,2-b]哒嗪-4-酮衍生物
JP2019532985A (ja) ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
WO2015178955A1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
EP3535268B1 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
JP2025538190A (ja) Ｅｇｆｒキナーゼの分解のための化合物
HK1234039A1 (en) Imidazotriazinone compounds
HK1187908B (en) Imidazotriazinone compounds
EP4640274A1 (en) Lpar1 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IRONWOOD PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: FORUM PHARMACEUTICALS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired